Financial Performance - The company's operating revenue for Q1 2025 was ¥101,731,108.99, a decrease of 26.19% compared to ¥137,834,311.82 in the same period last year[4] - Net profit attributable to shareholders increased by 106.03% to ¥8,852,007.80 from ¥4,296,554.68 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 126.25% to -¥1,144,397.72, down from ¥4,359,272.81 in the previous year[4] - Basic earnings per share increased by 100.00% to ¥0.02 from ¥0.01 year-on-year[6] - Diluted earnings per share also rose by 100.00% to ¥0.02 from ¥0.01 in the previous year[6] - Total revenue for Q1 2025 was CNY 101.73 million, a decrease of 26.2% compared to CNY 137.83 million in Q1 2024[19] - Net profit for Q1 2025 reached CNY 8.85 million, an increase of 108.5% from CNY 4.25 million in Q1 2024[21] - Earnings per share for Q1 2025 were CNY 0.02, compared to CNY 0.01 in Q1 2024[21] Cash Flow and Liquidity - The net cash flow from operating activities was -¥3,777,382.46, a decline of 171.65% compared to ¥5,271,978.33 in the same period last year[4] - Operating cash flow for Q1 2025 was negative at CNY -3.78 million, compared to a positive CNY 5.27 million in Q1 2024[24] - Cash received from sales of goods and services in Q1 2025 was CNY 115.61 million, down 20.3% from CNY 145.03 million in Q1 2024[24] - The net cash flow from investing activities was 21,442,432.69, compared to a negative cash flow of -192,236,008.94 in the previous period[25] - Cash inflow from financing activities totaled 79,900,000.00, an increase from 30,000,000.00 in the prior period[25] - The net cash flow from financing activities was 7,826,605.27, down from 28,577,347.66 in the previous period[25] - The total cash and cash equivalents at the end of the period amounted to 108,279,106.43, compared to 197,280,025.81 previously[25] - The net increase in cash and cash equivalents was 25,491,655.50, contrasting with a decrease of -158,386,682.95 in the prior period[25] - The company repaid debts amounting to 70,200,000.00, significantly higher than 100.00 in the previous period[25] - Dividends and interest payments totaled 1,873,394.73, compared to 1,322,652.34 previously[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,105,344,860.70, a slight decrease of 0.04% from ¥2,106,253,035.91 at the end of the previous year[6] - Total liabilities decreased to CNY 353,213,445.14 from CNY 377,473,002.37, showing a reduction in financial obligations[17] - Short-term borrowings decreased to CNY 89,649,147.21 from CNY 105,294,386.11, indicating a decrease in reliance on debt[17] - Total liabilities as of the end of the reporting period were CNY 506.07 million, a slight decrease from CNY 516.59 million in the previous period[18] Shareholder Information - The company reported a total of 30,473 common shareholders at the end of the reporting period[12] - The top shareholder, Shanghai Yanghe Industrial Co., Ltd., holds 20.82% of shares, amounting to 78,249,836 shares[12] - The company has no significant changes in the shareholding structure or related party transactions during the reporting period[13] Research and Development - Research and development expenses for Q1 2025 were CNY 9.24 million, a decrease of 23.9% from CNY 12.13 million in Q1 2024[20] Non-Recurring Gains - The company reported non-recurring gains totaling ¥9,996,405.52 for the period[9] Accounting Standards - The company will not apply new accounting standards starting from 2025[26]

浙江莎普爱思药业股份有限公司 2024 年度独立董事述职报告 作为浙江莎普爱思药业股份有限公司(以下简称"公司")的独立董事,在 2024 年度任职期间,本人严格按照《公司法》、《证券法》、《上市公司治理准 则》、《上市公司独立董事管理办法》等法律法规以及《公司章程》、《独立董 事工作细则》等公司制度的规定,重点关注公司财务状况、经营状况、业绩承诺 履行、股权激励、资产收购等情况,在报告期内勤勉、尽责、忠实履行职责,按 时出席相关会议,认真审议各项议案,对公司相关事项发表独立意见,切实维护 全体股东尤其是广大中小股东的合法权益。现将本人 2024 年度履职情况报告如 下: 一、 独立董事的基本情况 (一)工作履历、专业背景以及兼职情况 颜世富,男,1965出生,中国国籍,经济学博士,上海交通大学工商管理专 业博士研究生导师。编撰、主编、参编《东方管理学》《管理心理学》《绩效管 理》《高级人力资源管理师》《领导艺术》等 60 余本著作。在《管理世界》《心 理科学》等期刊发表 50 余篇论文。曾任北京大学国民素质研究中心执行主任, 复旦大学心理咨询中心常务副主任、上海交通大学行业研究院副院长。现任上海 交通大学东 ...

浙江莎普爱思药业股份有限公司 2024 年度独立董事述职报告 作为浙江莎普爱思药业股份有限公司(以下简称 "公司")的独立董事, 在 2024 年度任职期间,本人严格按照《公司法》、《证券法》、《上市公司治 理准则》、《上市公司独立董事管理办法》等法律法规以及《公司章程》、《独 立董事工作细则》等公司制度的规定,重点关注公司财务状况、经营状况、业绩 承诺履行、股权激励、资产收购等情况,在报告期内始终坚持诚信、勤勉、尽职 的原则,充分履行独立董事的职责,切实维护公司和股东的利益,积极推动董事 会规范运作和公司治理水平的提升。现将本人截至2024年5月15日的履职情况 报告如下: 一、 独立董事的基本情况 (一)工作履历、专业背景以及兼职情况 徐国彤先生,1957年出生,中国国籍,中国医学科学院北京协和医院医学博 士(眼科学)、美国北德克萨斯大学医学中心药理学系药理学博士,同济大学特 聘 教 授 、 博 士 生 导 师 。 曾 任 同 济 大 学 医 学 院 常 务 副 院 长 、 院 长 ; CellularBiomedicineGroup(NASDAQ:CBMG)独立董事。现任同济大学新生院济人 学堂执行院长 ...

Core Viewpoint - Zhejiang Shapuaisi Pharmaceutical Co., Ltd. reported a revenue of 484 million yuan for 2024 and 102 million yuan for Q1 2025, with a net profit of 8.852 million yuan, marking a year-on-year growth of 106.03% [1] Group 1: Financial Performance - In 2024, the company achieved a total revenue of 484 million yuan [1] - For Q1 2025, the revenue reached 102 million yuan, with a net profit of 8.852 million yuan, reflecting a significant increase of 106.03% year-on-year [1] Group 2: Strategic Focus - The company is focusing on a "healthcare" strategy, leveraging both internal innovation and external acquisitions to drive growth [1] - Shapuaisi is establishing a "pharmaceutical + medical" integration model to enhance its long-term development framework [1] Group 3: Product Development - The company is deepening its product line around core ophthalmic diseases, with stable sales from products like Benzoic Acid Eye Drops and Cefaclor Granules [1] - R&D investment for 2024 was 96.198 million yuan, accounting for 19.88% of total revenue, with a year-on-year increase of 5.42% [1] - Key projects in development include five major products: Atropine Sulfate Eye Drops, Pilocarpine Hydrochloride Eye Drops, Azithromycin Eye Drops, Latanoprost Eye Drops, and Cetirizine Hydrochloride Eye Drops [1] Group 4: Clinical Trials and Market Potential - Atropine Sulfate Eye Drops for controlling myopia in children are in Phase III clinical trials, with a projected market space exceeding 9 billion yuan by 2030 [2] - Pilocarpine Hydrochloride Eye Drops target presbyopia treatment, with 56.9% of the population over 35 affected, totaling approximately 390 million people [2] - Azithromycin Eye Drops received clinical trial approval for treating conjunctivitis, while Latanoprost and Cetirizine Hydrochloride Eye Drops were approved for dry eye syndrome and allergic conjunctivitis, respectively [2] Group 5: Expansion in Medical Services - The company is advancing its "pharmaceutical + medical" dual strategy by expanding into medical services through acquisitions [2] - Qingdao Shikang Eye Hospital has made significant progress in disciplines such as cataract and pediatric optometry, enhancing its diagnostic capabilities [3] - The acquisition of Taizhou Women and Children Hospital has allowed the company to extend its services into maternal and child healthcare, with ongoing expansion efforts [3]

Core Viewpoint - The company, Shapuaisi, reported significant revenue growth and strategic advancements in its business model, focusing on the integration of pharmaceuticals and medical services amidst various industry challenges [1][5]. Financial Performance - In 2024, the company achieved a revenue of 483.96 million yuan, while in the first quarter of 2025, it reported a revenue of 101.73 million yuan and a net profit attributable to shareholders of 8.85 million yuan, marking a year-on-year growth of 106.03% [1]. Research and Development - Shapuaisi is actively developing five core ophthalmic products, including atropine sulfate eye drops and pilocarpine hydrochloride eye drops, with a total R&D investment of 96.20 million yuan in 2024, representing 19.88% of its revenue [2][3]. - The atropine sulfate eye drops, aimed at controlling myopia progression in children, are currently in Phase III clinical trials, with a projected market space exceeding 9 billion yuan by 2030 [2]. - The pilocarpine hydrochloride eye drops target presbyopia treatment, with a significant potential market as there are currently no similar drugs approved in China [3]. Strategic Initiatives - The company is implementing a "pharmaceutical + medical" dual-driven strategy, enhancing its business through acquisitions and expanding into medical services [4]. - In 2023, Shapuaisi acquired 100% of Qingdao Vision Eye Hospital, strengthening its integrated service model in ophthalmology [4]. - The company also expanded into maternal and child healthcare by acquiring Taizhou Women and Children Hospital, enhancing its service capabilities with advanced medical technologies [4]. Industry Context - The company's strategic direction aligns with national health initiatives, addressing critical issues such as youth myopia prevention and aging population healthcare needs, indicating a promising growth outlook [5].

莎普爱思（603168）公告，2025年第一季度营收为1.02亿元，同比下降26.19%；净利润为885.2万元， 同比增长106.03%。 ...

证券代码：603168 证券简称：莎普爱思 公告编号：临2025-014 浙江莎普爱思药业股份有限公司 第六届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 浙江莎普爱思药业股份有限公司（以下简称"公司"）第六届监事会第七次会议于2025年4月10日以通讯 方式召开。全体监事同意豁免本次会议的通知时间要求。本次会议由许晓森先生主持，会议应出席监事 3人，实际出席监事3人。本次会议的召开符合《公司法》和《公司章程》等有关规定，会议决议合法、 有效。 经全体监事逐项审议，通过了如下议案： 1、审议通过《关于豁免第六届监事会第七次会议通知期限的议案》。 经全体监事审议和表决，同意豁免公司第六届监事会第七次会议的通知期限，并于2025年4月10日下午 召开第六届监事会第七次会议。 (表决情况：同意票3票、反对票0票、弃权票0票) 2、审议通过《关于出售全资孙公司股权的议案》。 鉴于浙江莎普爱思大药房连锁有限公司近年来持续亏损，且其主营业务与公司的战略方向有所偏离。为 进一步聚焦公司主营 ...

证券代码：603168 证券简称：莎普爱思 公告编号：临 2025-015 浙江莎普爱思药业股份有限公司 关于出售全资孙公司股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 本次交易概述 （一）基本情况 公司拟与万寿堂医药签署《股权转让合同》，将持有的目标公司 100%股权 以对价人民币 50 万元转让给万寿堂医药。本次股权转让完成后，公司将不再持 有目标公司股权，目标公司不再纳入公司合并报表范围。 2025 年 4 月 10 日，公司第六届董事会第七次会议审议通过了《关于出售全 资孙公司股权的议案》，董事会同意公司以 50 万元向受让方万寿堂医药转让所 持有的目标公司 100%股权，并授权公司管理层办理本次股权转让的具体事宜， 包括但不限于签署相关协议、办理工商变更等。 （四）本次交易不构成关联交易，也不构成《上市公司重大资产重组管理办 法》规定的重大资产重组。本次交易无需提交公司股东大会审议。 二、交易对方基本情况 （一）基本情况 公司名称：嘉兴市万寿堂医药连锁股份有限公司 统一社会信用代码 ...

经全体监事逐项审议，通过了如下议案： 证券代码：603168 证券简称：莎普爱思 公告编号：临 2025-014 浙江莎普爱思药业股份有限公司 第六届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 浙江莎普爱思药业股份有限公司（以下简称"公司"）第六届监事会第七次会议于 2025年4月10日以通讯方式召开。全体监事同意豁免本次会议的通知时间要求。本次会 议由许晓森先生主持，会议应出席监事3人，实际出席监事3人。本次会议的召开符合《公 司法》和《公司章程》等有关规定，会议决议合法、有效。 二、监事会会议审议情况 2025年4月11日 1、审议通过《关于豁免第六届监事会第七次会议通知期限的议案》。 经全体监事审议和表决，同意豁免公司第六届监事会第七次会议的通知期限，并于 2025年4月10日下午召开第六届监事会第七次会议。 (表决情况：同意票3票、反对票0票、弃权票0票) 2、审议通过《关于出售全资孙公司股权的议案》。 鉴于浙江莎普爱思大药房连锁有限公司近年来持续亏损，且其主营业务 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 经全体董事审议和表决，同意豁免公司第六届董事会第七次会议的通知期限，并于 2025年4月10日下午召开第六届董事会第七次会议。 一、董事会会议召开情况 浙江莎普爱思药业股份有限公司(以下简称"公司")第六届董事会第七次会议于2025 年4月10日下午以通讯方式召开，本次董事会的召开经全体董事同意豁免会议通知时间 要求。本次会议由董事长林弘立先生主持，会议应出席董事9人，实际出席董事9人。公 司监事、高级管理人员均知悉本次会议相关情况。本次会议的召开符合《公司法》和《公 司章程》等有关规定，会议决议合法、有效。 二、董事会会议审议情况 证券代码：603168 证券简称：莎普爱思 公告编号：临 2025-013 经全体董事逐项审议，通过了如下议案： 浙江莎普爱思药业股份有限公司 第六届董事会第七次会议决议公告 1、审议通过《关于豁免第六届董事会第七次会议通知期限的议案》。 详细内容请见公司在上海证券交易所网站（www.sse.com.cn）披露的《关于出售全 资孙公司股权的公告》（公 ...